Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase.

about

Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase.

Item

http://www.wikidata.org/entity/Q52620757

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Immunogenicity and Protection ...... emagglutinin or Neuraminidase.

@en

Immunogenicity and Protection ...... emagglutinin or Neuraminidase.

@nl

type

Item

label

Immunogenicity and Protection ...... emagglutinin or Neuraminidase.

@en

Immunogenicity and Protection ...... emagglutinin or Neuraminidase.

@nl

prefLabel

Immunogenicity and Protection ...... emagglutinin or Neuraminidase.

@en

Immunogenicity and Protection ...... emagglutinin or Neuraminidase.

@nl

P1476

Immunogenicity and Protection ...... emagglutinin or Neuraminidase.

@en

P2093

Clement A Meseda

http://www.w3.org/2001/XMLSchema#string

Jackeline Soto

http://www.w3.org/2001/XMLSchema#string

Jin Gao

http://www.w3.org/2001/XMLSchema#string

Vajini Atukorale

http://www.w3.org/2001/XMLSchema#string

Wei Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Modified Vaccinia Virus Ankara

Vectors based on modified vaccinia Ankara expressing influenza H5N1 hemagglutinin induce substantial cross-clade protective immunity

A pandemic influenza H1N1 live vaccine based on modified vaccinia Ankara is highly immunogenic and protects mice in active and passive immunizations

A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens

Human infection with a novel avian-origin influenza A (H7N9) virus

Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial.

Broad protection against avian influenza virus by using a modified vaccinia Ankara virus expressing a mosaic hemagglutinin gene

Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases

A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine.

MVA vectors expressing conserved influenza proteins protect mice against lethal challenge with H5N1, H9N2 and H7N1 viruses

P304

5364

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-018-23712-9

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Jerry P Weir

Carol D Weiss

Maryna C Eichelberger

P577

2018-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29599502

http://www.w3.org/2001/XMLSchema#string

P921

vector-borne disease

P932

5876369

http://www.w3.org/2001/XMLSchema#string